



# NRG1融合遺伝子陽性固形癌に対する 治療開発

名古屋大学大学院医学系研究科 呼吸器内科学  
森瀬 昌宏

# NRG1 fusion is Druggable Target




*Targeted inhibition of ERBB3/ERBB2 results in decreased growth of cell lines with NRG1 fusion*



*Cancer Discov. 2018;8(6):686-695.  
J Thorac Oncol. 2017;12(8):107-110.*

# Neuregulin 1 (NRG1) fusion is rare fraction

*Rate of NRG1 fusions  
by tumor type other than NSCLC*



**GBC: Gall Bladder Cancer,  
PDAC: Pancreatic Ductal Adeno Carcinoma,  
RCC: Renal Cell Carcinoma,  
Ovarian: Ovarian Cancer**

*Clin Cancer Res. 2019;15;25(16):4966-4972.*

# がん腫別の患者数とNRG1融合遺伝子陽性頻度

|           | 部位別癌死亡数<br>(2017) | NRG1 (incidence) |
|-----------|-------------------|------------------|
| 肺癌        | 74,120            | 0.7-0.5%         |
| 膵癌        | 34,224            | 0.5%             |
| 胆のう・胆管癌   | 18,179            | 0.5%             |
| 腎癌(腎がんなど) | 9,470             | 0.5%             |
| 卵巣癌       | 4,745             | 0.4%             |

# Approval of NGS genome profiling for solid tumors in Japan

Fusion genes in “NCC Onco-panel”

|            |             |             |              |              |              |                    |              |              |                    |
|------------|-------------|-------------|--------------|--------------|--------------|--------------------|--------------|--------------|--------------------|
| <i>ALK</i> | <i>AKT2</i> | <i>BRAF</i> | <i>ERBB4</i> | <i>FGFR2</i> | <i>FGFR3</i> | <b><i>NRG1</i></b> | <i>NTRK1</i> | <i>NTRK2</i> | <i>PDGFR<br/>A</i> |
|------------|-------------|-------------|--------------|--------------|--------------|--------------------|--------------|--------------|--------------------|

Comprehensive Genome Profiling Panel has just approved in Japan.



**NRG1 fusion solid tumors can be detected in clinical practice**  
**Non-small cell lung cancer, Gall Bladder Cancer,**  
**Pancreatic Ductal Adeno Carcinoma, Renal Cell Carcinoma,**  
**Ovarian Cancer**